comparemela.com
Home
Live Updates
Groupe Hospitalier Priv - Breaking News
Pages:
Latest Breaking News On - Groupe hospitalier priv - Page 1 : comparemela.com
Questionnaire Identifies Higher Risk of Biosimilar Treatment Discontinuation
Patients who completed the survey were significantly more likely to achieve 12-month persistence on adalimumab biosimilar SB5 when compared with non-respondents.
France general
Yoram bouhnik
Groupe hospitalier priv
Ambroise par
Perceived efficacy
Patient physician interactions
Infliximab Biosimilar Safe, Efficacious for Patients with IBD
In the infliximab reference group, the persistence at month 12 was 94% for Crohn’s disease and 92.8% for ulcerative colitis.
France general
Yoram bouhnik
Groupe hospitalier priv
Ambroise par
Therapeutic advances
vimarsana © 2020. All Rights Reserved.